Jonathan R. Strosberg, MD of the H. Lee Moffitt Cancer Center discusses the Phase III trial results of NETTER-1 as reported by the New England Journal of Medicine http://www.nejm.org/doi/full/10.1056/NEJMoa1607427CONCLUSIONS:
Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group.
NETTER-1 Phase III Trial Results Meet Primary Endppoint
